Apyx Medical (NASDAQ:APYX) Shares Break Above 50-Day Moving Average – Time to Sell?

Shares of Apyx Medical Corporation (NASDAQ:APYX) crossed above its 50-day moving average during trading on Thursday. The stock has a 50-day moving average of $2.74 and traded as high as $3.11. Apyx Medical shares last traded at $3.0450, with a volume of 994,957 shares traded.

More Apyx Medical News

Here are the key news stories impacting Apyx Medical this week:

• Positive Sentiment: Q3 revenue was $14.0 million, above the $13.29 million analyst estimate, while the loss of $0.04 per share was narrower than consensus estimates of $0.07–$0.09. Surgical Aesthetics revenue grew 17%. Apyx Medical Q3 2026 financial results
• Positive Sentiment: Management tightened its 2026 operating expense target to $41 million–$42.5 million, indicating a greater focus on cost control. Apyx reaffirms guidance and tightens expense target
• Neutral Sentiment: Apyx reaffirmed 2026 revenue guidance of $59 million–$60 million, broadly in line with the $59.4 million consensus estimate. The company also reported a successful commercial launch of its AYON power liposuction handpiece. Apyx Medical Q3 2026 financial results
• Negative Sentiment: The company continued to post a quarterly loss and has negative net margins, so sustained revenue growth and expense control will be important to improving profitability.

Analysts Set New Price Targets

APYX has been the subject of several recent analyst reports. HC Wainwright assumed coverage on Apyx Medical in a research note on Monday, July 13th. They issued a “buy” rating and a $7.00 price target for the company. Maxim Group began coverage on Apyx Medical in a report on Tuesday, September 29th. They issued a “buy” rating and a $6.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Apyx Medical in a research report on Monday, September 21st. Finally, Zacks Research upgraded Apyx Medical to a “hold” rating in a research report on Tuesday, July 14th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $6.50.

Apyx Medical Trading Up 17.6%

The company has a 50 day simple moving average of $2.74 and a 200 day simple moving average of $3.59. The company has a market capitalization of $128.27 million, a PE ratio of -15.22 and a beta of 1.47. The company has a debt-to-equity ratio of 3.19, a quick ratio of 4.53 and a current ratio of 5.68.

Apyx Medical (NASDAQ:APYX) last released its earnings results on Thursday, November 5th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.05. The business had revenue of $14.03 million for the quarter, compared to the consensus estimate of $13.29 million. Apyx Medical had a negative return on equity of 76.60% and a negative net margin of 14.78%. Analysts anticipate that Apyx Medical Corporation will post -0.25 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Nantahala Capital Management LLC purchased a new position in Apyx Medical in the 2nd quarter valued at $14,683,414. AIGH Capital Management LLC acquired a new stake in Apyx Medical during the 2nd quarter worth $5,066,000. BlackRock Inc. acquired a new stake in Apyx Medical during the 2nd quarter worth $2,519,000. Sei Investments Co. boosted its stake in Apyx Medical by 298.6% during the 1st quarter. Sei Investments Co. now owns 598,255 shares of the company’s stock worth $2,208,000 after purchasing an additional 448,174 shares during the last quarter. Finally, Kingsview Wealth Management LLC acquired a new stake in Apyx Medical during the 2nd quarter worth $962,000. 55.33% of the stock is owned by institutional investors and hedge funds.

Apyx Medical Company Profile

Apyx Medical Corporation develops and commercializes energy-based medical technologies for use in surgical and aesthetic procedures. The company’s platform is based on helium plasma technology, which is designed to deliver controlled energy for soft-tissue coagulation, cutting, and contraction.

Apyx Medical’s principal product line is Renuvion, a system that combines helium plasma with radiofrequency energy. Renuvion devices and handpieces are used by physicians in a range of surgical and aesthetic applications, including procedures intended to coagulate tissue and address skin laxity.